Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01734928 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

559

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Pomalidomide
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Celgene